Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemose...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2018-01, Vol.59 (1), p.85-96
Main Authors: Hazar, Volkan, Kesik, Vural, Karasu, Gülsün Tezcan, Öztürk, Gülyüz, Küpesiz, Alphan, Kılıç, Suar Çakı, Ataş, Erman, Uygun, Vedat, Eker, Nurşah, Erbey, Fatih, Bengoa, Şebnem Yılmaz, Emir, Suna, Anak, Sema, Öniz, Haldun, Daloğlu, Hayriye, Aksoylar, Serap, Koçak, Ülker, Karakükçü, Musa, Elli, Murat, Kurucu, Nilgün, Yeşilipek, Akif
Format: Article
Language:English
Subjects:
Adolescent
Child
Child, Preschool
children and adolescents
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Non-Hodgkin - epidemiology
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Male
Neoplasm Staging
Prognosis
Recurrence
Registries
Relapsed or refractory non-Hodgkin lymphoma
Retrospective Studies
Risk Factors
Transplantation, Homologous
Treatment Outcome
Turkey - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3
cites cdi_FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3
container_end_page 96
container_issue 1
container_start_page 85
container_title Leukemia & lymphoma
container_volume 59
creator Hazar, Volkan
Kesik, Vural
Karasu, Gülsün Tezcan
Öztürk, Gülyüz
Küpesiz, Alphan
Kılıç, Suar Çakı
Ataş, Erman
Uygun, Vedat
Eker, Nurşah
Erbey, Fatih
Bengoa, Şebnem Yılmaz
Emir, Suna
Anak, Sema
Öniz, Haldun
Daloğlu, Hayriye
Aksoylar, Serap
Koçak, Ülker
Karakükçü, Musa
Elli, Murat
Kurucu, Nilgün
Yeşilipek, Akif
description We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p 
doi_str_mv 10.1080/10428194.2017.1330472
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_10428194_2017_1330472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1905740206</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3</originalsourceid><addsrcrecordid>eNp9UUuP1CAAbozGXVd_goajl87yamk9aTbqmmxiYtYzoUCnOC0g0Gn6w71Ld2aN8eAJEr4nX1G8RnCHYAOvEaS4QS3dYYjYDhECKcNPiksEcVtiCsnT7U5xuYEuihcx_oAQVm2NnxcXuKkYqjC-LH59M_EAeiGTCxH4oJWRydg9SIMGcQ5HcxQjcD3w-UWkYCTwIhltUwSLSQMIehQ-anUddB8eZFZgnS1vndofjAXjOvnBTQIsgwOzVTosmQwGPYnkvDM6ZcmY9ASkHkeQgrDRj8Km7OLsOyCyQwouep1zHXOmNKsV9MFNDxHv53AwcfgrXuesBpMIwS3_qmWpvYkprC-LZ70Yo351Pq-K758-3t_clndfP3-5-XBXSlLXqWwo6SXGHauElKonrNF1TVilG6gQJkxSxQTuFGKQUVopRbuKtG0NGwGRVB25Kt6edH1wP2cdE59M3HoKq90cOWphxSjEsM7Q6gSVuWzMn8l9MLnGyhHk2-L8cXG-Lc7Pi2fem7PF3E1a_WE9TpwB708AY3sXJrG4MCqexDq6kBez0kRO_u_xG5vnw_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1905740206</pqid></control><display><type>article</type><title>Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Hazar, Volkan ; Kesik, Vural ; Karasu, Gülsün Tezcan ; Öztürk, Gülyüz ; Küpesiz, Alphan ; Kılıç, Suar Çakı ; Ataş, Erman ; Uygun, Vedat ; Eker, Nurşah ; Erbey, Fatih ; Bengoa, Şebnem Yılmaz ; Emir, Suna ; Anak, Sema ; Öniz, Haldun ; Daloğlu, Hayriye ; Aksoylar, Serap ; Koçak, Ülker ; Karakükçü, Musa ; Elli, Murat ; Kurucu, Nilgün ; Yeşilipek, Akif</creator><creatorcontrib>Hazar, Volkan ; Kesik, Vural ; Karasu, Gülsün Tezcan ; Öztürk, Gülyüz ; Küpesiz, Alphan ; Kılıç, Suar Çakı ; Ataş, Erman ; Uygun, Vedat ; Eker, Nurşah ; Erbey, Fatih ; Bengoa, Şebnem Yılmaz ; Emir, Suna ; Anak, Sema ; Öniz, Haldun ; Daloğlu, Hayriye ; Aksoylar, Serap ; Koçak, Ülker ; Karakükçü, Musa ; Elli, Murat ; Kurucu, Nilgün ; Yeşilipek, Akif</creatorcontrib><description>We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p &lt; .001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428194.2017.1330472</identifier><identifier>PMID: 28571522</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Adolescent ; Child ; Child, Preschool ; children and adolescents ; Drug Resistance, Neoplasm ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, Non-Hodgkin - epidemiology ; Lymphoma, Non-Hodgkin - mortality ; Lymphoma, Non-Hodgkin - pathology ; Lymphoma, Non-Hodgkin - therapy ; Male ; Neoplasm Staging ; Prognosis ; Recurrence ; Registries ; Relapsed or refractory non-Hodgkin lymphoma ; Retrospective Studies ; Risk Factors ; Transplantation, Homologous ; Treatment Outcome ; Turkey - epidemiology</subject><ispartof>Leukemia &amp; lymphoma, 2018-01, Vol.59 (1), p.85-96</ispartof><rights>2017 Informa UK Limited, trading as Taylor &amp; Francis Group 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3</citedby><cites>FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3</cites><orcidid>0000-0002-1407-2334</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28571522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hazar, Volkan</creatorcontrib><creatorcontrib>Kesik, Vural</creatorcontrib><creatorcontrib>Karasu, Gülsün Tezcan</creatorcontrib><creatorcontrib>Öztürk, Gülyüz</creatorcontrib><creatorcontrib>Küpesiz, Alphan</creatorcontrib><creatorcontrib>Kılıç, Suar Çakı</creatorcontrib><creatorcontrib>Ataş, Erman</creatorcontrib><creatorcontrib>Uygun, Vedat</creatorcontrib><creatorcontrib>Eker, Nurşah</creatorcontrib><creatorcontrib>Erbey, Fatih</creatorcontrib><creatorcontrib>Bengoa, Şebnem Yılmaz</creatorcontrib><creatorcontrib>Emir, Suna</creatorcontrib><creatorcontrib>Anak, Sema</creatorcontrib><creatorcontrib>Öniz, Haldun</creatorcontrib><creatorcontrib>Daloğlu, Hayriye</creatorcontrib><creatorcontrib>Aksoylar, Serap</creatorcontrib><creatorcontrib>Koçak, Ülker</creatorcontrib><creatorcontrib>Karakükçü, Musa</creatorcontrib><creatorcontrib>Elli, Murat</creatorcontrib><creatorcontrib>Kurucu, Nilgün</creatorcontrib><creatorcontrib>Yeşilipek, Akif</creatorcontrib><title>Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry</title><title>Leukemia &amp; lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p &lt; .001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.</description><subject>Adolescent</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children and adolescents</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Lymphoma, Non-Hodgkin - epidemiology</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Lymphoma, Non-Hodgkin - pathology</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Registries</subject><subject>Relapsed or refractory non-Hodgkin lymphoma</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><subject>Turkey - epidemiology</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UUuP1CAAbozGXVd_goajl87yamk9aTbqmmxiYtYzoUCnOC0g0Gn6w71Ld2aN8eAJEr4nX1G8RnCHYAOvEaS4QS3dYYjYDhECKcNPiksEcVtiCsnT7U5xuYEuihcx_oAQVm2NnxcXuKkYqjC-LH59M_EAeiGTCxH4oJWRydg9SIMGcQ5HcxQjcD3w-UWkYCTwIhltUwSLSQMIehQ-anUddB8eZFZgnS1vndofjAXjOvnBTQIsgwOzVTosmQwGPYnkvDM6ZcmY9ASkHkeQgrDRj8Km7OLsOyCyQwouep1zHXOmNKsV9MFNDxHv53AwcfgrXuesBpMIwS3_qmWpvYkprC-LZ70Yo351Pq-K758-3t_clndfP3-5-XBXSlLXqWwo6SXGHauElKonrNF1TVilG6gQJkxSxQTuFGKQUVopRbuKtG0NGwGRVB25Kt6edH1wP2cdE59M3HoKq90cOWphxSjEsM7Q6gSVuWzMn8l9MLnGyhHk2-L8cXG-Lc7Pi2fem7PF3E1a_WE9TpwB708AY3sXJrG4MCqexDq6kBez0kRO_u_xG5vnw_w</recordid><startdate>20180102</startdate><enddate>20180102</enddate><creator>Hazar, Volkan</creator><creator>Kesik, Vural</creator><creator>Karasu, Gülsün Tezcan</creator><creator>Öztürk, Gülyüz</creator><creator>Küpesiz, Alphan</creator><creator>Kılıç, Suar Çakı</creator><creator>Ataş, Erman</creator><creator>Uygun, Vedat</creator><creator>Eker, Nurşah</creator><creator>Erbey, Fatih</creator><creator>Bengoa, Şebnem Yılmaz</creator><creator>Emir, Suna</creator><creator>Anak, Sema</creator><creator>Öniz, Haldun</creator><creator>Daloğlu, Hayriye</creator><creator>Aksoylar, Serap</creator><creator>Koçak, Ülker</creator><creator>Karakükçü, Musa</creator><creator>Elli, Murat</creator><creator>Kurucu, Nilgün</creator><creator>Yeşilipek, Akif</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1407-2334</orcidid></search><sort><creationdate>20180102</creationdate><title>Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry</title><author>Hazar, Volkan ; Kesik, Vural ; Karasu, Gülsün Tezcan ; Öztürk, Gülyüz ; Küpesiz, Alphan ; Kılıç, Suar Çakı ; Ataş, Erman ; Uygun, Vedat ; Eker, Nurşah ; Erbey, Fatih ; Bengoa, Şebnem Yılmaz ; Emir, Suna ; Anak, Sema ; Öniz, Haldun ; Daloğlu, Hayriye ; Aksoylar, Serap ; Koçak, Ülker ; Karakükçü, Musa ; Elli, Murat ; Kurucu, Nilgün ; Yeşilipek, Akif</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children and adolescents</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Lymphoma, Non-Hodgkin - epidemiology</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Lymphoma, Non-Hodgkin - pathology</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Registries</topic><topic>Relapsed or refractory non-Hodgkin lymphoma</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hazar, Volkan</creatorcontrib><creatorcontrib>Kesik, Vural</creatorcontrib><creatorcontrib>Karasu, Gülsün Tezcan</creatorcontrib><creatorcontrib>Öztürk, Gülyüz</creatorcontrib><creatorcontrib>Küpesiz, Alphan</creatorcontrib><creatorcontrib>Kılıç, Suar Çakı</creatorcontrib><creatorcontrib>Ataş, Erman</creatorcontrib><creatorcontrib>Uygun, Vedat</creatorcontrib><creatorcontrib>Eker, Nurşah</creatorcontrib><creatorcontrib>Erbey, Fatih</creatorcontrib><creatorcontrib>Bengoa, Şebnem Yılmaz</creatorcontrib><creatorcontrib>Emir, Suna</creatorcontrib><creatorcontrib>Anak, Sema</creatorcontrib><creatorcontrib>Öniz, Haldun</creatorcontrib><creatorcontrib>Daloğlu, Hayriye</creatorcontrib><creatorcontrib>Aksoylar, Serap</creatorcontrib><creatorcontrib>Koçak, Ülker</creatorcontrib><creatorcontrib>Karakükçü, Musa</creatorcontrib><creatorcontrib>Elli, Murat</creatorcontrib><creatorcontrib>Kurucu, Nilgün</creatorcontrib><creatorcontrib>Yeşilipek, Akif</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia &amp; lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hazar, Volkan</au><au>Kesik, Vural</au><au>Karasu, Gülsün Tezcan</au><au>Öztürk, Gülyüz</au><au>Küpesiz, Alphan</au><au>Kılıç, Suar Çakı</au><au>Ataş, Erman</au><au>Uygun, Vedat</au><au>Eker, Nurşah</au><au>Erbey, Fatih</au><au>Bengoa, Şebnem Yılmaz</au><au>Emir, Suna</au><au>Anak, Sema</au><au>Öniz, Haldun</au><au>Daloğlu, Hayriye</au><au>Aksoylar, Serap</au><au>Koçak, Ülker</au><au>Karakükçü, Musa</au><au>Elli, Murat</au><au>Kurucu, Nilgün</au><au>Yeşilipek, Akif</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry</atitle><jtitle>Leukemia &amp; lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2018-01-02</date><risdate>2018</risdate><volume>59</volume><issue>1</issue><spage>85</spage><epage>96</epage><pages>85-96</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p &lt; .001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>28571522</pmid><doi>10.1080/10428194.2017.1330472</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-1407-2334</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1042-8194
ispartof Leukemia & lymphoma, 2018-01, Vol.59 (1), p.85-96
issn 1042-8194
1029-2403
language eng
recordid cdi_crossref_primary_10_1080_10428194_2017_1330472
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Adolescent
Child
Child, Preschool
children and adolescents
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Non-Hodgkin - epidemiology
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Male
Neoplasm Staging
Prognosis
Recurrence
Registries
Relapsed or refractory non-Hodgkin lymphoma
Retrospective Studies
Risk Factors
Transplantation, Homologous
Treatment Outcome
Turkey - epidemiology
title Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A10%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20predicting%20the%20survival%20of%20pediatric%20patients%20with%20relapsed/refractory%20non-Hodgkin%20lymphoma%20who%20underwent%20hematopoietic%20stem%20cell%20transplantation:%20a%20retrospective%20study%20from%20the%20Turkish%20pediatric%20bone%20marrow%20transplantation%20registry&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Hazar,%20Volkan&rft.date=2018-01-02&rft.volume=59&rft.issue=1&rft.spage=85&rft.epage=96&rft.pages=85-96&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428194.2017.1330472&rft_dat=%3Cproquest_cross%3E1905740206%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-843fc22b75accdf378e66375e80d1237c4d7a2bd1707445dd4b5399608a01cdb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1905740206&rft_id=info:pmid/28571522&rfr_iscdi=true